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Abstract
Introduction: Cardiovascular agents are pivotal in the therapy of heart failure. Apart from their action on ventricular
contractility and systemic afterload, they affect pulmonary arteries and veins. Although these effects are crucial in heart
failure with coexisting pulmonary hypertension or lung oedema, they are poorly defined, especially in pulmonary veins.
Therefore, we investigated the pulmonary vascular effects of adrenoceptor agonists, vasopressin and angiotensin II in the
model of precision-cut lung slices that allows simultaneous studies of pulmonary arteries and veins.
Materials and Methods: Precision-cut lung slices were prepared from guinea pigs and imaged by videomicroscopy.
Concentration-response curves of cardiovascular drugs were analysed in pulmonary arteries and veins.
Results: Pulmonary veins responded stronger than arteries to a1-agonists (contraction) and b2-agonists (relaxation).
Notably, inhibition of b2-adrenoceptors unmasked the a1-mimetic effect of norepinephrine and epinephrine in pulmonary
veins. Vasopressin and angiotensin II contracted pulmonary veins via V1a and AT1 receptors, respectively, without affecting
pulmonary arteries.
Discussion: Vasopressin and (nor)epinephrine in combination with b2-inhibition caused pulmonary venoconstriction. If
applicable in humans, these treatments would enhance capillary hydrostatic pressures and lung oedema, suggesting their
cautious use in left heart failure. Vice versa, the prevention of pulmonary venoconstriction by AT1 receptor antagonists
might contribute to their beneficial effects seen in left heart failure. Further, a1-mimetic agents might exacerbate pulmonary
hypertension and right ventricular failure by contracting pulmonary arteries, whereas vasopressin might not.
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Introduction
Treatment of acute and chronic heart failure is based on the
therapy with cardiovascular agents that aim at improved
ventricular contractility, enhanced coronary perfusion and re-
duced myocardial oxygen consumption. Importantly however,
cardiovascular agents interact with the pulmonary vascular bed
and thereby also influence myocardial function: First, contraction
of pulmonary arteries (PAs) enhances right ventricular afterload
and worsens right ventricular failure. Second, contraction of
pulmonary veins (PVs) increases pulmonary capillary pressure and
causes hydrostatic pulmonary oedema and deterioration of gas
exchange. Thus, it is clinically important how PAs and PVs
respond to cardiovascular agents. However, the differential effects
of cardiovascular drugs along the pulmonary vascular bed are only
incompletely defined. Most previous studies focused on PAs [1–5],
probably due to their central role in pulmonary hypertension and
right ventricular failure. Recently, PVs are receiving growing
attention and their relevance in the regulation of total pulmonary
vascular resistance is becoming evident [6]. Therefore, and due to
completely different responses of PAs and PVs [7], simultaneous
studies of both vessels are of great clinical interest; however, they
are rare [4]. Further, pulmonary vessels differ from systemic
vessels in their response to hypoxia, hypercapnia and acidosis [8],
thus results from systemic vessels may not be applicable to the low
pressure pulmonary vascular bed.
The aim of this study was to investigate the effects of
adrenoceptor agonists, vasopressin and angiotensin II on PAs
and PVs. We have chosen the model of precision-cut lung slices
(PCLS), because it permits simultaneous studies of PAs and PVs.
Further, guinea pigs (GPs) were chosen, because previous studies
on airway pharmacology suggest that GPs may be a reasonable
proxy of human lung tissue [9]. Our results indicate that GPs’ PAs
and PVs respond significantly different to adrenoceptor agonists,
vasopressin and angiotension II. These findings suggest that
differential effects of cardiovascular drugs along the pulmonary
vascular tree might influence the success of heart failure therapy.
Materials and Methods
Guinea pigs (GPs)
Female Dunkin Hartley GPs (400650 g) were obtained from
Charles River (Sulzfeld, Germany) and held under standard
conditions. All animal care and experimental procedures were
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Aachen (Aachen, Germany) and the Directive 2010/63/EU of the
European Parliament. They were approved by the Landesamt fu ¨r
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen
(LANUV, approval-ID: 8.87–51.05.20.10.245).
Precision-cut lung slices (PCLS)
PCLS from GPs (n=39) were prepared as described before [9].
In brief, intraperitoneal anaesthesia was performed with 95 mg
kg
21 pentobarbital (Narcoren; Garbsen, Germany) and its depth
was monitored by missing reflexes. Afterwards, the abdomen was
opened and the GP exsanguinated. Further, the trachea was
cannulated, the diaphragm opened and the lungs filled with low
melting point agarose (final concentration: 1.5%), containing
1 mM isoproterenol. To solidify the agarose, the lungs were
covered with ice. The lobes were removed; tissue cores prepared
and cut into 300 mm thick slices with a Krumdieck tissue slicer
(Alabama Research & Development, Munford, AL, USA).
Afterwards, PCLS were incubated at 37uC in a humid atmosphere
in minimal essential medium (MEM), containing CaCl2 (1.8 mM),
MgSO4 (0.8 mM), KCl (5.4 mM), NaCl (116.4 mM), glucose
(16.7 mM), NaHCO3 (26.1 mM), Hepes (25.17 mM), sodium
pyruvate, amino acids, vitamins and glutamine. To wash out the
agarose from the slices, the MEM was changed every half hour
during the first 2 h and every hour during the next 2 h. For
overnight culture, MEM was completed with penicillin and
streptomycin and changed every 24 h.
Identification of the vessels, histology
Pulmonary vessels were identified using the following criteria:
PAs accompany the airways and PVs lie aside. After staining with
haematoxylin and eosin (HE) PAs show a wrinkled inner lining
and a thick media wall [7], as it is illustrated in Fig. 1A–D. Thus,
after termination of the experiments PCLS were fixed in 4%
formalin and embedded in paraffin. Sections (4 mM) were cut and
HE-stained. Images were taken by a microscope (Leica, DM
600 B).
Measurements and Imaging
At the beginning of the study, all agents were investigated with
regard to the onset of their maximal contractile or relaxant effect.
According to these results, the duration of exposure was defined
for all agents, i.e. for (nor)epinephrine, isoproterenol, phenyleph-
rine, procaterol, denopamine, CL 316243 and A 61603 3 minutes,
for vasopressin 5 minutes and for angiotensin 10 minutes. The
slices were exposed to different drugs on day one and two after
preparation. Concentration-response curves were performed on
pulmonary arteries and veins and cross sectional area of the vessels
was calculated. Control experiments were performed on consec-
utive sections. Pulmonary vessels were imaged and digitised using
a digital video camera (Leica Viscam 1280 or Leica DFC 280).
The images were analysed with Optimas 6.5 (Media Cybernetics,
Bothell, WA).
Agents
All agents were purchased from Sigma-Aldrich (Steinheim,
Germany), except CGP 20712 A, procaterol and CL 316243,
which were from Tocris Bioscience (Ellisville, Missouri, USA).
Statistics
Statistics was conducted using SAS software version 9.1 (SAS
Institute, Cary, North Carolina, USA) and GraphPad Prism
version 5.0 (GraphPad Software, La Jolla, USA). Homoscedastic-
ity of values was evaluated. Changes of the vessel area are
expressed as percentage of its initial area. All values are shown as
mean 6 SEM. Paired observations were analysed using the one
sample t-test or the Wilcoxon signed rank test. Unpaired
observations were compared using the Mann-Whitney Test.
When the effect of increasing concentrations on the vessels was
roughly linear, data were analysed using a linear mixed model
analysis (LMM). In case of sigmoidal concentration-response
curves; the standard logistic regression model was used to calculate
and compare EC50 values. For LMM and logistic regression the
AIC-criterion was used to select the preferred model. All p-values
were adjusted for multiple comparisons by the false discovery rate
[10]. P-values ,0.05 were considered as significant. For all
experiments, (n) indicates the numbers of animals.
Results
Stimulation of a- and b-receptors in PAs and PVs
The endogenous vasoactive compounds norepinephrine and
epinephrine [(nor)epinephrine] represent cardiovascular agents,
that are worldwide most commonly used to restore circulation in
cardiac failure and shock.
In PAs, (nor)epinephrine induced maximal contraction at 1 mM,
though epinephrine was more potent. Above 1 mM this difference
disappeared, suggesting the additional activation of b2-adrenocep-
tors by epinephrine (Fig. 2A). Pre-treatment of PAs with the a1-
antagonist prazosine (100 nM) prevented (nor)epinephrine-in-
duced contraction (Fig. 2A). Comparable to norepinephrine, the
a1-agonist phenylephrine induced only slight contraction in PAs
(Fig. 2B). Similar results were obtained for the a1-agonist A 61603,
whereas the a2-agonist clonidine had no effect (not shown). Pre-
treatment of PAs with the selective b2-antagonist ICI 118551
(100 nM) enhanced norepinephrine-induced contraction and
10 mM ICI 118551 had an even stronger effect (Fig. 2C).
However, ICI 118551 at 100 nM (Fig. 2D) or 10 mM (not shown)
did not alter the effect of epinephrine. The b1/2-agonist
isoproterenol had no effect in PAs (Fig. 2C), whereas the pure
b2-agonist procaterol relaxed them (Fig. 2D). Further, procaterol
completely abolished contraction due to (nor)epinephrine (Fig. 2C/
Figure 1. Identification of pulmonary vessels. A) A representative
PCLS after staining with haematoxylin and eosin. B) epithelium of an
airway (AW) C) Pulmonary artery (PA): endothelium with typical
wrinkled inner lining and thick media D) Pulmonary vein (PV):
endothelium without wrinkled inner lining and thin media E)
corresponding unstained PCLS.
doi:10.1371/journal.pone.0029698.g001
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(1 mM) shifted epinephrine-induced contraction rightwards, with-
out altering its maximal effect (Fig. 2E). Pre-treatment with the b1-
antagonist CGP 20712A (100 nM) abolished epinephrine-induced
contraction (Fig. 2E). However, the b1-agonist denopamine had no
effect on PAs. Further, denopamine given as pre-treatment prior
to increasing concentrations of phenylephrine did not enhance
phenylephrine-induced contraction (Fig. 2F). Also the b3-agonist
CL 316243 had no effect (Fig. 2E). Finally, the tone of PAs was not
affected by prazosine, CGP 20712A, ICI 118551 and propanolol
(Table 1).
In PVs, isoproterenol, procaterol, norepinephrine and epineph-
rine causedrelaxation,withthefollowingEC50values:isoproterenol
0.26 mM, procaterol 0.12 mM, norepinephrine 30 mM and epi-
nephrine 1 mM (Fig. 3A). Simultaneous treatment with epinephrine
and the pure b2-agonist procaterol did not enhance epinephrine-
induced relaxation (Fig. 3B). Further, combined treatment with
norepinephrine and procaterol did not alter the maximal relaxant
effect of norepinephrine; however EC50 values were shifted
leftwards to lower concentrations, i.e. EC50 values were 8.6 nM
for simultaneous treatment with procaterol and norepinephrine
instead of 30 mM for norepinephrine alone. Pre-treatment with
100 nM prazosine had no effect alone (Table 1) or on epinephrine-
induced relaxation (Fig. 3B), but enhanced the effect of norepi-
nephrine (Fig. 3C). When PVs were pre-treated with the b2-
antagonist ICI 118551 (10 mM or 100 nM) the effect of (nor)epi-
nephrine was reversed and it became contractile (Fig. 3B/C). At
1 mM epinephrine showed some relaxation despite the presence of
ICI 118551 (Fig. 3B). Similar results were obtained for (nor)epi-
nephrine after pre-treatment with 1 mM propanolol (not shown).
Neither ICI 118551 nor propanolol did affect the basal tone of PVs
(Table 1). The a1-agonist A 61603 contracted PVs, whereas the a1-
agonist phenylephrine had only a slight contractile effect at 10 mM
that was reversed at higher concentrations (Fig. 3D). However, after
pre-treatment with 100 nM ICI 118551 PVs responded to
phenylephrine comparable to A 61603 (Fig. 3D). In addition, the
a2-agonist clonidine, the b1-agonist denopamine and the b3-agonst
CL 316243 had no effects in PVs (not shown).
Effects of vasopressin on PAs and PVs
The neurohypophyseal peptide vasopressin contracts vascular
smooth muscles via binding to V1a receptors. PVs, but not PAs,
contracted to vasopressin (EC50: 2 pM, Fig. 4A/B). The
cyclooxygenase inhibitor indomethacin (10 mM) attenuated vaso-
pressin-induced contraction. Conversely, the NO synthase inhib-
itor N-nitro-L-arginine methyl ester (L-NAME, 100 mM) showed a
trend towards enhancement (Fig. 4B). However, neither L-NAME
nor indomethacin changed the vascular responses of PAs to
vasopressin (Fig. 4A). Pre-treatment of PVs with the V1a antagonist
SR 49059 (10 nM) showed no effect alone (Table 1), but abolished
contraction due to vasopressin (Fig. 4B). Further, the NO-donor S-
Nitroso-N-acetyl-DL-penicillamine (SNAP) partly reversed vaso-
pressin-induced contraction in PVs (Fig. 4B). Indomethacin
slightly contracted PVs (Table 1) and L-NAME induced time-
dependent contraction (Fig. 5A), which was reversed by SNAP.
Further, native PVs also relaxed to SNAP (Fig. 5B), whereas PAs
did not react to L-NAME or SNAP (Fig. 5A/B).
Effects of angiotensin II on PAs and PVs
Angiotensin II induces vasoconstriction via the G-protein
coupled AT1 receptor. Angiotensin II contracted PVs (EC50:
0.1 nM; Fig. 6B–D), but not PAs (Fig. 6A). Pre-treatment with
indomethacin (10 mM) or L-NAME (100 mM) did not alter the
response of pulmonary vessels to angiotensin II (Fig. 6A–C). In
order to analyse, whether angiotensin-induced contraction is
specific to AT1 binding, PCLS were pre-treated with the AT1
antagonist losartan. Losartan (1 mM) had no effect alone, but
abolished the effect of angiotensin II (Fig. 6D, Table 1).
Discussion
(Nor)epinephrine and vasopressin are clinically relevant cardio-
vascular agents that are daily applied in the treatment of acute
haemodynamic instability. Further, angiotensin-converting en-
zyme inhibitors and AT1 antagonists are used to treat chronic
heart failure. Commonly, their effects on systemic circulation are
well controlled; whereas their pulmonary vascular effects are rarely
assessed, especially in PVs. However this entity is of relevance,
especially in pulmonary hypertension and right heart failure. This
study compared the pulmonary vascular effects of (nor)epineph-
rine, vasopressin and angiotensin II in PCLS of GPs. Adrenergic
agonists contracted PAs and PVs, but their contractile effect on
PVs was unmasked only in the presence of b2-inhibition.
Vasopressin and angiotensin II only contracted PVs.
Table 1. Influence of various antagonists and inhibitors on the initial vessel area.
agents PA mean (%) n SEM p-value PV mean (%) n SEM p-value
prazosine 100 nM 102 8 3.7 0.64 103 8 3.2 0.33
CGP 20712 A 100 nM 101 5 1.3 0.81 102 5 1.5 0.31
ICI 188551 10 mM 101 6 1.2 1 95 9 5.5 0.34
ICI 188551 100 nM 100 10 1.2 0.7 97 10 3.5 0.38
propanolol 1 mM 97 8 1.2 0.06 93 9 4.7 0.16
indomethacin 10 mM 98 7 0.9 0.15 95 9 1.1 0.001
SR 49059 10 nM 102 3 3.2 1 101 3 1.4 1
losartan 1 mM 100 4 2.4 1 98 4 1.2 0.25
Observations were paired, thus statistics was conducted using the One sample t-test or the Wilcoxon Test. P,0.05 are considered as statistical significant.
doi:10.1371/journal.pone.0029698.t001
Figure 2. Responses of pulmonary arteries (PAs) to increasing dosages of adrenergic agents. A-F) Pre-treatment concentrations were
fixed. P,0.05 are considered as statistical significant and are indicated as followed p,0.05, p,0.01 and p,0.001.
doi:10.1371/journal.pone.0029698.g002
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(Nor)epinephrine interacted with a1/b1/2-adrenoceptors of PAs
and PVs. (Nor)epinephrine-related contraction of PAs was
inhibited by prazosine and thus most likely caused by activation
of a1-adrenoceptors. In addition, inhibition of ß1-adrenoceptors
abolished epinephrine-induced contraction, suggesting their in-
volvement in a1-mediated contraction. This somewhat surprising
conclusion is supported by two findings: First, a1/b1/2-agonists
such as (nor)epinephrine contracted PAs stronger than phenyl-
ephrine and A 61603, which selectively act on a1-adrenoceptors in
PAs. Second, the selective b2-agonist procaterol relaxed PAs,
whereas the b1/2-agonist isoproterenol did not, suggesting
neutralization of b1-mediated contraction by b2-mediated relax-
ation. Concurrent activation of a1/b1-adrenoceptors was before
reported in PVs [11], albeit with regard to ectopic activity.
Previously, isoproterenol that binds stronger on b1-adrenoceptors
than on b2-adrenoceptors [12] was observed to contract vessels
[13]. Of note, the b1-agonist denopamine failed to contract PAs or
to enhance phenylephrine-induced contraction. These findings
suggest a complex and indirect activation of b1-adrenoceptors by
epinephrine that remains to be further elucidated.
Interestingly, the contractile potency of epinephrine decreased
above 1 mM indicating the additional activation of b2-adrenocep-
tors and subsequent vasorelaxation. This conclusion is supported
by the effects of procaterol that relaxed PAs and prevented
epinephrine- and norepinephrine-induced contraction. Further,
treatment of PAs with ICI 118551 enhanced norepinephrine-
related contraction. Thus, vasoconstriction appears to be partially
masked by stimulation of b2-adrenoceptors. In contrast, ICI
118551 did not alter epinephrine-induced contraction. Possibly,
epinephrine at 1 mM mainly acts as a relatively pure a1-agonist,
whereas above 1 mM it competes with ICI 118551 for b2-
adrenoceptors.
Thus, adrenergic agents interact in a complex manner with a1/
b1/2-adrenoceptors of PAs (Table 2). Contraction is mainly
mediated by a1-adrenoceptors, but is antagonised by b2-adreno-
ceptors and aggravated by b1-adrenoceptors.
The pulmonary venous vascular bed contributes up to 40% to
total pulmonary vascular resistance [6]. In PVs, b2-adrenoceptors
appear to be dominant and mask the activation of a1-
adrenoceptors (Table 2). This is concluded from the observation
that PVs contracted to (nor)epinephrine and phenylephrine only in
Figure 3. Responses of pulmonary veins (PV) to adrenergic agents. A)( ) isoproterenol (n=5); (N) epinephrine (n=6); (X) procaterol (n=7);
( ) norepinephrine (n=6); B)(N) epinephrine (n=6); (&) prazosine (100 nM), epinephrine (n=6); ( ) ICI 118551 (100 nM), epinephrine (n=5); (e)
ICI 118551 (10 mM), epinephrine (n=5); ( ) procaterol, epinephrine (n=4); C)( #) norepinephrine (n=6); (%) prazosine (100 nM), norepinephrine
(n=3); ( ) ICI 118551 (100 nM), norepinephrine (n=9); (N) ICI 118551 (10 mM), norepinephrine (n=6); ( ) procaterol, norepinephrine (n=4); D)( #)
phenylephrine (n=6); ( ) A 61603 (n=5), (%) ICI 118551 (100 nM), phenylephrine (n=5). Asterics indicate different EC50.values of the various curves.
P,0.05 are considered as statistical significant and are indicated as followed p,0.05, p,0.01 and p,0.001.
doi:10.1371/journal.pone.0029698.g003
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indomethacin (10 mM), vasopressin (n=4); (&) L-NAME (100 mM), vasopressin (n=5) B) PV: (N) vasopressin (n=5); ( ) indomethacin (10 mM),
vasopressin (n=4); (&) L-NAME (100 mM), vasopressin (n=5); ( ) SR 49059 (10 nM), vasopressin (n=3). C) PV: (N) vasopressin (n=5); ( ) vasopressin,
SNAP (n=7). D) PV: vasopressin, SNAP (n=7). B) Asterics indicate different EC50.values of the various curves. C–D) Statistics was performed using the
Wilcoxon test. For all: P,0.05 are considered as statistical significant and are indicated as followed p,0.05, p,0.01 and p,0.001.
doi:10.1371/journal.pone.0029698.g004
Figure 5. Responses of pulmonary arteries (PAs) and pulmonary veins (PVs) to L-NAME and SNAP. A)(N) PV (n=3); (#) PA (n=3). B)
(N) PV (n=3); (#) PA (n=3). Statistics was conducted using a linear mixed model analysis. P-values were adjusted for multiple comparisons by the
false discovery rate. P,0.05 are considered as statistical significant and indicated as followed p,0.05, p,0.01 and p,0.001.
doi:10.1371/journal.pone.0029698.g005
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relaxant, whereas phenylephrine was not, which is in line with its
weak b2-affinity. Pre-treatment with prazosine only enhanced the
relaxant effect of norepinephrine. Probably, maximal relaxation of
epinephrine was already reached, as it stimulates b2-adrenoceptors
more potently than norepinephrine [12]. Further, combined
treatment with procaterol and epinephrine did not alter
epinephrine-induced relaxation in PVs, probably due to similar
binding affinities in respect of the b2-receptor [14]. However, as
expected, simultaneous treatment with procaterol and norepi-
Figure 6. Responses of pulmonary arteries (PAs) and pulmonary veins (PVs) to angiotensin II. A) PA: (N) angiotensin II (n=6); ( )
indomethacin (10 mM), angiotensin II (n=5); (&) L-NAME (100 mM), angiotensin II (n=5) B) PV: (N) angiotensin II (n=5); (&) L-NAME (100 mM),
angiotensin II (n=5) C) PV: (N) angiotensin II (n=5); ( ) indomethacin (10 mM), angiotensin II (n=5) D) PV: (N) angiotensin II (n=5); ( ) losartan
(1 mM), angiotensin II (n=3); (#) losartan (10 nM), angiotensin II (n=3). Asterics indicate different EC50.values of the various curves. P,0.05 are
considered as statistical significant and are indicated as followed p,0.05, p,0.01 and p,0.001.
doi:10.1371/journal.pone.0029698.g006
Table 2. Overview of cardiovascular agents and their receptor-mediated vascular effects.
agents PA/contraction PA/relaxation PV/contraction PV/relaxation
epinephrine 1 mM a1 (ß1)( a1) b2
norepinephrine 1 mM a1 (a1) b2
epinephrine 1 mM a1 b2 (a1) b2
norepinephrine 1 mM (a1)( b2)( a1) b2
phenylephrine a1 (a1)( b2)
A 61603 a1 a1
procaterol – b2 – b2
.1 pM vasopressin –– V 1a –
angiotensin II –– A T 1 –
NO –– –N O
Masked effects are expressed with ().
doi:10.1371/journal.pone.0029698.t002
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line with the high binding affinity of procaterol to the b2-receptor
[14].
Our results may help to put previous findings into perspective.
In perfused feline lung lobes, norepinephrine and phenylephrine
enhanced pulmonary vascular resistance; while epinephrine and
isoproterenol had the opposite effect [15]. These results might
reflect the net effect of a1-dependent pulmonary arterial
contraction versus b2-dependent pulmonary venous relaxation.
Though, in perfused rat lungs norepinephrine and phenylephrine
reduced the pulmonary perfusion pressure [5], likely due to b2-
mediated relaxation [16].
Beta2-mediated pulmonary venous relaxation is of clinical
interest, as mixed b1/2-blockers are widely-used. Commonly, a1/
ß1/2-agonists, such as (nor)epinephrine are applied in heart failure
or shock. However, if these patients are pre-treated with mixed
b1/2-blockers, circulation support with (nor)epinephrine might
worsen gas exchange, due to pulmonary venoconstriction, as
(nor)epinephrine mainly activate a1-adrenoceptors, while ß2-
adrenoceptors are still blocked. In pulmonary hypertension,
(nor)epinephrine might increase right ventricular afterload and
aggravate right ventricular failure. If these findings could be
confirmed in humans, this should be considered in the therapy of
heart failure.
Vasopressin
Vasopressin has various physiological functions, including V1a
receptor-mediated regulation of blood pressure and V2 receptor-
mediated control of body water [17]. Further, its relevance in
resuscitation is increasingly discussed. Here, vasopressin only
contracted PVs. Inhibition of endothelial NO-synthase (eNOS)
tended to enhance this contractile effect and the NO-donor SNAP
reversed it in part. Further, L-NAME given alone also contracted
PVs. This indicates the critical role of eNOS in PVs as opposed to
arteries, similar to observations in human [18] and porcine PVs
[19]. Moreover, indomethacin attenuated the effect of vasopressin,
indicating its partial action through the release of contractile
prostanoids such as thromboxane.
In contrast to our results, vasopressin relaxed PAs in isolated
perfused rat lungs [3] and isolated canine pulmonary vessels in
dependence to eNOS [1,4]. In dogs, it contracted PAs [2].
Vasopressin contracts vessels via V1a receptor-mediated phospo-
lipase C activation and IP3-signalling [17] and opposing to our
results, the involvement of relaxant prostaglandins was shown
[20]. Thus, the effect of vasopressin in pulmonary vessels may
strongly depend on the studied species [21]. Best to our
knowledge, pulmonary venous contraction due to vasopressin
was not yet reported.
Interestingly, human data indirectly support our results [22]:
application of vasopressin led to enhanced pulmonary capillary
wedge pressures (PCWP). Vice versa, application of the V1a/2
antagonist conivaptan decreased PCWP [23], whereas the V2
antagonist tolvaptan did not, but increased vasopressin plasma
levels [24]. Thus, vasopressin antagonists that do not block V1a
receptors might be problematic. In patients with heart failure,
vasopressin plasma levels are increased up to 0.28 nM [25],
concentrations that contracted PVs in our in vitro model. Hence,
vasopressin-related contraction of PVs might enhance pulmonary
hydrostatic pressures, left ventricular preload and wall stress.
Taken together, our findings suggest that V1a antagonists might
reduce pulmonary complications in heart failure and further, that
vasopressin might not worsen right ventricular afterload (Table 2).
Angiotensin II
Angiotensin II is the key peptide of the renin-angiotensin system
and mainly produced in the pulmonary arterial vascular bed [26].
In the present study, angiotensin II only contracted the PVs; neither
inhibition of NO- nor prostanoid synthesis altered this response.
In contrast to our results, angiotensin contracted endothelium
denuded, isolated PAs of GPs and dogs [4,27,28], whereas canine
PVs relaxed [4] or failed to respond [28]. Moreover, indomethacin
enhanced the contractile effect of angiotensin in PAs [4]. In line
with our results, angiotensin contracted rat PVs [29]. Further, in
patients with atrial and ventricular septum defects, angiotensin
increased left atrial and pulmonary venous pressures, but did not
alter the pulmonary arterial resistance [30]. In addition, only the
extent of left to right shunts increased. According to our results,
pulmonary venoconstriction might be a reasonable explanation for
these observations. Prevention of pulmonary venous contraction
by AT1 antagonists or ACE-inhibitors might contribute to their
beneficial effect in heart failure.
PCLS from GPs
Thus, our findings are in line with clinical studies and suggest
that PCLS from GPs resemble human pulmonary vascular
pharmacology reasonably well, as already indicated for airway
pharmacology [9]. This study was performed in vitro and thus
excludes factors that affect vascular responses in vivo such as shear
stress or embolism. In vivo, the PA can be accessed by
catheterization, whereas the access of PVs is more difficult. The
PCWP relates to left atrial pressure and to large PVs, but small
PVs are not reflected [31]. Further, vascular pressure represents a
product of vascular tone and filling. Hence, it is influenced by
ventricular contractility. Complementary to in vivo studies, PCLS
allow exclusively studying the vascular tone of pulmonary vessels.
For the first time, this study systematically compared the effects
of clinically relevant cardiovascular agents simultaneously on PAs
and PVs. Our results indicate that PAs and PVs are contracted by
a1-agonists, while relaxation, which occurs predominantly in PVs,
is mediated by b2-adrenoceptors. Of note, b1-adrenoceptors
contribute to adrenergic contraction in PAs. Further, vasopressin
and angiotensin target predominantly PVs and thus raise the
hypothesis that activation of V1a receptors and AT1 receptors
favours pulmonary oedema. Thus, clinically, the application of
vasopressin in left heart failure should be faced with caution and
conversely suggests a beneficial role of V1a and AT1 antagonists. In
contrast to vasopressin, (nor)epinephrine may increase right
ventricular afterload, but not pulmonary oedema, except in
patients pre-treated with b1/2-inhibitors. Taken together, both
vascular beds exhibit important differences in their responses to
cardiovascular drugs. In conclusion, successful restoration of
circulation in heart failure and shock should take into account
the differential effects of cardiovascular agents on PAs and PVs.
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